FDA accepts for Review New Drug Application (NDA) for gefapixant for treatment of refractory or unexplained chronic cough in adults

NDA for this investigational, orally administered, selective P2X3 receptor antagonist, is based on results from COUGH-1 and COUGH-2 trials, in patients with a cough that persists despite appropriate treatment of underlying conditions or where underlying cause cannot be identified

Source:

Biospace Inc.